A Study of the Safety and Efficacy of Long-term Correction of Anemia With Epoetin Alfa in Early Hemodialysis Patients

NCT00261521 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

596

Enrollment

INDUSTRY

Sponsor class

Conditions

Kidney Failure, Chronic
Anemia

Interventions

DRUG: epoetin alfa

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.